Symphogen Opens US Operations in Princeton, New Jersey - Gilde Healthcare

Symphogen Opens US Operations in Princeton, New Jersey

3 November 2009

-US Subsidiary Supports Expanding Opportunities for Symphogen’s Novel Antibody Pipeline and Discovery and Expression Platforms-

COPENHAGEN, Denmark and PRINCETON, NJ – Symphogen A/S today announced the opening of its United States headquarters in Princeton, New Jersey. Adriann Sax, Symphogen’s recently appointed Chief Business Officer, will head the Company’s US business which will operate as Symphogen, Inc., a wholly-owned subsidiary of Symphogen A/S.

“This is the optimal time to strengthen Symphogen’s global presence as our novel pipeline is advancing into the later-stages of clinical development,”

said Kirsten Drejer, Ph.D., CEO of Symphogen.
Ms. Sax added,

“Antibody therapeutics and technologies continue to drive significant value for the pharmaceutical industry.  New Jersey has long been recognized as good centralized location for bioscience companies with global development programs and multiple worldwide partnerships, so it was an easy decision for Symphogen to base our US business here.  With Symphogen’s growing pipeline and leading antibody discovery and expression technologies, we are excited about the company’s future prospects and hope to capitalize on these opportunities by having broad access to physicians, patients and partners.”

About Symphogen

Symphogen is developing superior antibody therapeutics to help people with serious diseases.  With its proprietary SymplexTM discovery and SympressTM manufacturing platforms, the company captures the diversity and specificity of the natural immune response in rationally designed recombinant antibody compositions.  Symphogen is maturing a diversified pipeline of internal and partnered products across multiple indications including cancer and infectious disease.  Symphogen is a private biopharmaceutical company with more than 70 employees, and its headquarters are based in Copenhagen, Denmark.  www.symphogen.com

Gilde Healthcare Private Equity as part of Investor Consortium acquires DETAX

Specialist for medical polymer materials DETAX resolves ownership succession in the course of a management buy-out and continues its successful growth track together with a strong Investor Consortium DETAX is a leading global supplier of...
3 December 2021

Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Building the team with experienced biotech experts and renowned leaders in the ADC field Underscores company’s commitment to progressing lead program on novel ADC target uPARAP Adcendo, a biotech company focused on the development of...
1 December 2021

Gilde Healthcare company Sanifit acquired by Vifor Pharma

Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, complementing and strengthening the Group’s growing nephrology portfolio Sanifit’s lead compound, SNF472 is a novel, first-in-class inhibitor...
22 November 2021